Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

Blood

Volumn 124, Issue 7, 2014, Pages 1062-1069

  Rumi, Elisa ^a,b   Pietra, Daniela ^a   Pascutto, Cristiana ^a   Guglielmelli, Paola ^c   Martínez Trillos, Alejandra ^d   Casetti, Ilaria ^b   Colomer, Dolors ^d   Pieri, Lisa ^c   Pratcorona, Marta ^d   Rotunno, Giada ^c   Sant'Antonio, Emanuela ^b   Bellini, Marta ^b   Cavalloni, Chiara ^b   Mannarelli, Carmela ^c   Milanesi, Chiara ^a   Boveri, Emanuela ^a   Ferretti, Virginia ^a   Astori, Cesare ^a   Rosti, Vittorio ^a   Cervantes, Francisco ^d   Barosi, Giovanni ^a   Vannucchi, Alessandro M ^c   Cazzola, Mario ^a,b   more..

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; HEMOGLOBIN; JANUS KINASE 2; THROMBOPOIETIN RECEPTOR; JAK2 PROTEIN, HUMAN; MPL PROTEIN, HUMAN;

ADULT; AGED; ANEMIA; ARTICLE; EXON; FEMALE; FOLLOW UP; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INDEL MUTATION; LEUKOCYTE COUNT; LEUKOCYTOSIS; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; ADOLESCENT; CELL TRANSFORMATION; COMPLICATION; GENETICS; KAPLAN MEIER METHOD; LEUKEMIA; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CALRETICULIN; CELL TRANSFORMATION, NEOPLASTIC; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; JANUS KINASE 2; KAPLAN-MEIER ESTIMATE; LEUKEMIA; LEUKOCYTOSIS; MALE; MIDDLE AGED; MUTATION; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, THROMBOPOIETIN; RISK ASSESSMENT; RISK FACTORS; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 84905990634     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-578435     Document Type: Article

References (34)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
2. Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98(12):3249-3255.
3. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
4. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
5. Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014;123(24):3714-3719.
6. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379- 2390.
7. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405.
8. Lasho TL, Jimma T, Finke CM, et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012;120(20):4168-4171.
9. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861-1869.
10. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-1132. (Pubitemid 41323513)
11. Marchioli R, Finazzi G, Specchia G, et al CYTOPV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.
12. Vannucchi AM, Antonioli E, Guglielmelli P, et al MPD Research Consortium. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21(9):1952-1959. (Pubitemid 47299969)
13. Malcovati L, Della Porta MG, Pietra D, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood. 2009;114(17):3538-3545.
14. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574-1579.
15. Pietra D, Brisci A, Rumi E, et al. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica. 2011;96(4):607-611.
16. Rumi E, Pietra D, Ferretti V, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544-1551.
17. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34(4):541-554. (Pubitemid 9067879)
18. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med. 1993;12(8):737-751. (Pubitemid 23134304)
19. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
20. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19(6):716-723.
21. Barosi G, Bergamaschi G, Marchetti M, et al; Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Italian Registry of Myelofibrosis. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007;110(12):4030-4036. (Pubitemid 350248459)
22. Rotunno G, Mannarelli C, Guglielmelli P, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552- 1555.
23. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472-1477.
24. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28(7):1494-1500.
25. Andrikovics H, Krahling T, Balassa K, et al. Distinct clinical characteristics in myeloproliferative neoplasms with calreticulin mutations. Haematologica. 2014;99(7):1184-1190.
26. Della Porta MG, Malcovati L. Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. Haematologica. 2009;94(5):602-606.
27. Della Porta MG, Travaglino E, Boveri E, et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes [published online ahead of print May 20, 2014]. Leukemia.
28. Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123(22):e123-e133.
29. Vannucchi AM, Rotunno G, Bartalucci N, et al. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value [published online ahead of print March 12, 2014]. Leukemia.
30. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91(2):169-175.
31. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD341 cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107(9):3676-3682.
32. Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220-2228.
33. Papaemmanuil E, Gerstung M, Malcovati L, et al Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-3627, quiz 3699.
34. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122(25):4021-4034.